Disease · MONDO_0005625

cerebral malaria

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. cerebral malaria. Diseases, record MONDO_0005625. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005625

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: cerebral malaria; Open Targets
Open Targets ID: MONDO_0005625; Open Targets
Disease Ontology: DOID:14069; Disease Ontology
MeSH: D016779; MeSH
NCI Thesaurus: C128373; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 1 of its 6 drugs, from ClinicalTrials.gov; Open Targets

Drugs6

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
SODIUM CHLORIDE	CHEMBL1200574	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
LEVETIRACETAM	CHEMBL1286	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
NITRIC OXIDE	CHEMBL1200689	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
PENTOXIFYLLINE	CHEMBL628	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
PHENOBARBITAL	CHEMBL40	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
6-DIAZO-5-OXO-L-NORLEUCINE	CHEMBL97485	Small molecule	Phase 1/2	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets30

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ADORA2A	Adenosine A2 receptor	1	Adenosine A2 receptor antagonist	Phase 2	https://conductscience.org/library/genes/135	Drugs and targets
ADORA2B	Adenosine A2 receptor	1	Adenosine A2 receptor antagonist	Phase 2	https://conductscience.org/library/genes/136	Drugs and targets
CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1B	1	Voltage-gated N-type calcium channel alpha-1B subunit blocker	Phase 2	https://conductscience.org/library/genes/774	Drugs and targets
GUCY1A1	Soluble guanylate cyclase	1	Soluble guanylate cyclase activator	Phase 2	https://conductscience.org/library/genes/2982	Drugs and targets
GUCY1A2	Soluble guanylate cyclase	1	Soluble guanylate cyclase activator	Phase 2	https://conductscience.org/library/genes/2977	Drugs and targets
GUCY1B1	Soluble guanylate cyclase	1	Soluble guanylate cyclase activator	Phase 2	https://conductscience.org/library/genes/2983	Drugs and targets
PDE10A	3',5'-cyclic phosphodiesterase	1	3',5'-cyclic phosphodiesterase inhibitor	Phase 2	https://conductscience.org/library/genes/10846	Drugs and targets
PDE1A	3',5'-cyclic phosphodiesterase	1	3',5'-cyclic phosphodiesterase inhibitor	Phase 2	https://conductscience.org/library/genes/5136	Drugs and targets
PDE1B	3',5'-cyclic phosphodiesterase	1	3',5'-cyclic phosphodiesterase inhibitor	Phase 2	https://conductscience.org/library/genes/5153	Drugs and targets
PDE1C	3',5'-cyclic phosphodiesterase	1	3',5'-cyclic phosphodiesterase inhibitor	Phase 2	https://conductscience.org/library/genes/5137	Drugs and targets

1 to 10 of 30

See all 30 targets

Trials6

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03300648	Treating Brain Swelling in Pediatric Cerebral Malaria	Phase 3	57	2025-03-17	Malaria, Cerebral	SODIUM CHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT01982812	A Safety and Feasibility Study of Enteral LVT vs. Standard of Care for Seizure Control in Pediatric CM	Phase 2	44	2016-07-29	Seizure, Epilepsy, Cerebral Malaria	LEVETIRACETAM, PHENOBARBITAL	Its record names the disease	ClinicalTrials.gov
NCT01660672	Enteral Levetiracetam For Seizure Control In Pediatric Cerebral Malaria	Phase 1/2	7	2014-10-17	Seizure, Epilepsy, Cerebral Malaria	LEVETIRACETAM	Its record names the disease	ClinicalTrials.gov
NCT05478720	DON in Pediatric Cerebral Malaria	Phase 1/2	152		Malaria, Cerebral	6-DIAZO-5-OXO-L-NORLEUCINE	Its record names the disease	ClinicalTrials.gov
NCT01388842	Evaluation of the Efficacy and Safety of Inhaled Nitric Oxide as Adjunctive Treatment for Cerebral Malaria in Children	Phase 2	92		Malaria, Cerebral	NITRIC OXIDE	Its record names the disease	ClinicalTrials.gov
NCT00133393	Pentoxifylline in Children With Malaria	Phase 2	50		Plasmodium Falciparum Malaria	PENTOXIFYLLINE	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials1

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial
Oral Levetiracetam vs Comparison Group: serious adverse events	5 of 23	8 of 21	44	NCT01982812

Source Trial comparisons

Papers from its trials4

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
41748157	RESULT	1	PubMed
38279124	DERIVED	1	PubMed
34020114	DERIVED	1	PubMed
31672143	DERIVED	2	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005625

GET https://conductscience.org/api/diseases/v1/MONDO_0005625/targets?page=2

API reference For AI assistants